EGFR and non-small cell lung carcinoma: In conclusion, our current preclinical study of WB-308 demonstrated that WB-308, a novel small molecule inhibitor, functions similarly to Gefitinib, and impairs the kinase activity of EGFR, thus inhibiting human NSCLC cell growth.